| |
NewswireToday - /newswire/ -
Winston-Salem, NC, United States, 10/21/2009 - SmallCapReview.com a leading site for small cap information is adding Entest Biomedical (OTCBB: ENTB) to its list of stocks "On the Radar".
|
| |
Entest Biomedical (ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. The Company is involved with the development of testing procedures for diabetes, stem cell research applications for diabetes, traumatic brain injury and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).
ENTB works closely and shares facilities with Bio-Matrix Scientific Group Inc., which is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.
The Company is currently in the process of procuring grants from various organizations for conducting research in the area of adipose (fat) derived stem cell treatments for traumatic brain injuries. There are currently no effective therapeutic approaches to reverse these injuries. Entest BioMedical has an exclusive license from UCLA to develop a streamline test for Gestational Diabetes (potentially impacting 4.3 million pregnant women each year).
ENTB Investor Highlights
ENTB is the exclusive licensee, granted by UCLA of a gestational diabetes screening test developed by a UCLA researcher. There are approximately 4.3 million live births in the U.S. per year. Statistics show that out of every 100 pregnant women, 3 to 8 will develop gestational diabetes. Hospitals and clinics represent a large potential market in the U.S. for this non-invasive, reliable, and highly accurate screening test. The Company is currently in the process of developing a large scale sampling for validation by the FDA.
Bio-Matrix Scientific and Entest BioMedical, are working with Therinject to develop immuno-therapeutic cancer treatments initially intended for veterinary applications while gathering data in support of human clinical trials.
The cost of treating Chronic Obstructive Pulmonary Disease (COPD) is projected to exceed $800 billion over the next 20 years. ENTB's stem cell therapy, if proven effective, can provide a strong revenue base for the Company while substantially reducing the cost of treating COPD.
ENTB announced that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).
ENTB anticipates its treatment option could have marked effects on the human oncology market, which the National Cancer Institute (NCI) estimated at more than $72 billion in 2004.
In 2009, NCI’s SEER Cancer Statistics Review estimates that more than 1.4 million men and women in United States will be diagnosed with cancer.
ENTB has plans to develop a commercially viable treatment for canines, which could impact approximately 36 million dogs in United States that suffer from cancer, according to the Morris Animal Foundation and the American Veterinary Medical Association.
Bio-Matrix announced that it has retained a private grant research and development firm to aggressively pursue both private and public sector grant funding of research in the area of Stem Cell Therapy for COPD conducted by Entest BioMedical, Inc.
Bio-Matrix Scientific is in the process of forming a relationship with a medical device manufacturer that produces encapsulation devices to be used in a study developed by ENTB on an immuno-therapeutic cancer vaccine.
Bio-Matrix Scientific announced that the Company and Therinject LLC have begun development of a tumor banking facility. Tumor banking will allow storage and ease of sourcing for tumor cells to be utilized in cancer vaccines.
ENTB filed a patent application for the use of adipose (fat) derived stem cells in the treatment of COPD.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has been compensated up to three thousand five hundred dollars by a third party RDI for its services with regards to Entest Biomedical.
|
editor[.]smallcapreview.com 
